According to NICE guidelines, the diagnosis of asthma in adults should include bronchodilator reversibility testing, while children aged 5-16 should also undergo this test if feasible. Fractional exhaled nitrous oxide (FeNO) testing is not recommended as the initial step for diagnosing asthma in children, but may be considered in cases of diagnostic uncertainty where spirometry is normal or obstructive with negative bronchodilator reversibility. Methacholine bronchial challenge is not used in children and should only be considered in adults if other tests have not provided a clear diagnosis. Peak flow readings may be offered in children aged 5-16 with normal or obstructive spirometry and positive FeNO. While symptoms may indicate asthma, further objective testing is necessary, starting with spirometry and bronchodilator reversibility testing in children aged 5-16. A diagnosis of asthma in this age group may be made with positive bronchodilator reversibility or positive FeNO with positive peak flow variability.

Asthma diagnosis has been updated by NICE guidelines in 2017, which emphasizes the use of objective tests rather than subjective/clinical judgments. The guidance recommends the use of fractional exhaled nitric oxide (FeNO) test, which measures the level of nitric oxide produced by inflammatory cells, particularly eosinophils. Other established objective tests such as spirometry and peak flow variability are still important. All patients aged five and above should have objective tests to confirm the diagnosis. For patients aged 17 and above, spirometry with a bronchodilator reversibility (BDR) test and FeNO test should be performed. For children aged 5-16, spirometry with a BDR test and FeNO test should be requested if there is normal spirometry or obstructive spirometry with a negative BDR test. For patients under five years old, diagnosis should be made based on clinical judgment. The specific points about the tests include a FeNO level of >= 40 ppb for adults and >= 35 ppb for children considered positive, and a FEV1/FVC ratio less than 70% or below the lower limit of normal considered obstructive for spirometry. A positive reversibility test is indicated by an improvement in FEV1 of 12% or more and an increase in volume of 200 ml or more for adults, and an improvement in FEV1 of 12% or more for children.

If an ex-smoker experiences shortness of breath, weight loss, and hyponatremia, urgent investigation for lung cancer is necessary, even if their chest x-ray appears normal. This recommendation is in line with the current guidelines from NICE. Although gastrointestinal cancer cannot be ruled out, the absence of chronic blood loss indicated by a normal MCV is not entirely conclusive.

Referral Guidelines for Lung Cancer

Lung cancer is a serious condition that requires prompt diagnosis and treatment. The 2015 NICE cancer referral guidelines provide clear advice on when to refer patients for suspected lung cancer. According to these guidelines, patients should be referred using a suspected cancer pathway referral for an appointment within 2 weeks if they have chest x-ray findings that suggest lung cancer or are aged 40 and over with unexplained haemoptysis.

For patients aged 40 and over who have 2 or more unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, an urgent chest x-ray should be offered within 2 weeks to assess for lung cancer. This recommendation also applies to patients who have ever smoked and have 1 or more of these unexplained symptoms.

In addition, patients aged 40 and over with persistent or recurrent chest infection, finger clubbing, supraclavicular lymphadenopathy or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis should be considered for an urgent chest x-ray within 2 weeks to assess for lung cancer.

Overall, these guidelines provide clear and specific recommendations for healthcare professionals to identify and refer patients with suspected lung cancer for prompt diagnosis and treatment.

The diagnosis of COPD cannot be determined through peak expiratory flow.

Investigating and Diagnosing COPD

To diagnose COPD, NICE recommends considering patients over 35 years of age who are smokers or ex-smokers and have symptoms such as chronic cough, exertional breathlessness, or regular sputum production. The following investigations are recommended: post-bronchodilator spirometry to demonstrate airflow obstruction, chest x-ray to exclude lung cancer and identify hyperinflation, bullae, or flat hemidiaphragm, full blood count to exclude secondary polycythaemia, and BMI calculation. The severity of COPD is categorized using the FEV1, with Stage 1 being mild and Stage 4 being very severe. Measuring peak expiratory flow is of limited value in COPD as it may underestimate the degree of airflow obstruction. It is important to note that the grading system has changed following the 2010 NICE guidelines, with Stage 1 now including patients with an FEV1 greater than 80% predicted but a post-bronchodilator FEV1/FVC ratio less than 70%.

For this patient with pre-existing asthma, an immediate or delayed antibiotic prescription should be considered due to the higher risk of complications. The first-line antibiotic for acute bronchitis is oral doxycycline, unless the patient is pregnant or a child. As this patient has normal observations and no focal respiratory signs, same-day admission is not necessary, and treatment can be provided in the community without intravenous antibiotics or oxygen.

Reassuring the patient and prescribing carbocisteine is not recommended as mucolytics are not effective for managing acute cough caused by acute bronchitis. Administering IM amoxicillin is also not appropriate as doxycycline is the recommended first-choice antibiotic for this condition, and IM is an invasive route that is unnecessary for this patient who can swallow.

Understanding Acute Bronchitis

Acute bronchitis is a chest infection that is typically self-limiting and caused by inflammation of the trachea and major bronchi. This results in swollen airways and the production of sputum. The condition usually resolves within three weeks, but some patients may experience a cough for longer. Viral infections are the leading cause of acute bronchitis, with most cases occurring in the autumn or winter.

Symptoms of acute bronchitis include a sudden onset of cough, sore throat, runny nose, and wheezing. While most patients have a normal chest examination, some may experience a low-grade fever or wheezing. It is important to differentiate acute bronchitis from pneumonia, which may present with sputum, wheezing, and breathlessness.

Acute bronchitis is typically diagnosed based on clinical presentation, but CRP testing may be used to guide antibiotic therapy. Management of acute bronchitis includes analgesia, good fluid intake, and consideration of antibiotic therapy for patients who are systemically unwell, have pre-existing co-morbidities, or have a CRP level indicating the need for antibiotics. Doxycycline is the first-line antibiotic recommended by NICE Clinical Knowledge Summaries/BNF, but it cannot be used in children or pregnant women. Alternatives include amoxicillin.

Understanding Stridor and its Association with Lung Cancer

Stridor is a respiratory sound characterized by a loud, harsh, and high-pitched noise. It is usually heard during inspiration and is caused by a partial obstruction of the airway, particularly in the trachea, larynx, or pharynx. In severe cases of upper airway obstruction, stridor may also occur during expiration, indicating tracheal or bronchial obstruction within the thoracic cavity.

Lung cancer is one of the conditions that can cause stridor, particularly small cell carcinomas that grow rapidly and metastasize to mediastinal lymph nodes early in the disease’s course. Patients with lung cancer may present with large intra-thoracic tumors, making it difficult to distinguish the primary tumor from lymph node metastases. The pressure on mediastinal structures can cause various symptoms, including hoarseness, hemi-diaphragm paralysis, dysphagia, and stridor due to compression of the major airways. Understanding the association between stridor and lung cancer can help in the early detection and management of the disease.

Treatment Options and Risks for Obstructive Sleep Apnoea

Obstructive sleep apnoea (OSA) is a condition that affects breathing during sleep, leading to interrupted sleep and daytime fatigue. In the UK, the Uvulopalatopharyngoplasty (UPPP) treatment is used for simple snoring, while in the USA, it is used to treat OSA with a success rate of around 65%. Tonsillectomy can also benefit some cases. However, successful treatment with continuous positive airways pressure (CPAP) is the most effective way to reduce the risk of road traffic accidents (RTA) to normal levels and doesn’t exclude the sufferer from holding any type of driving licence. The risk of RTA, untreated, is estimated to be eight times normal. OSA is also associated with hypothyroidism and acromegaly, according to a study published in the Medicine Journal in May 2008. It is important to consider the various treatment options and risks associated with OSA to manage the condition effectively.

Identifying the Correct Diagnosis for Breathlessness

A variety of conditions can cause breathlessness, making it difficult to arrive at a correct diagnosis. For instance, someone with shortness of breath and bibasal crepitations may be misdiagnosed with heart failure. However, a normal ECG and BNP can rule out cardiac failure.

To identify the correct diagnosis, a thorough clinical examination is necessary. In this case, the presence of finger clubbing narrows the options down to bronchiectasis, carcinoma, and pulmonary fibrosis. The additional features of cyanosis and bibasal fine crepitations strongly suggest that pulmonary fibrosis is the underlying diagnosis.

By carefully considering all the symptoms and conducting a comprehensive examination, healthcare professionals can accurately diagnose and treat patients with breathlessness.

NICE Guidance on Hospital Admission for Acute Asthma Exacerbations

When it comes to acute asthma exacerbations, it is important to know when hospital admission is necessary. According to NICE guidance, a life-threatening asthma exacerbation is an obvious reason for hospitalization. However, there are cases where a severe or even moderate attack may require hospital monitoring and treatment.

NICE advises clinicians to consider hospital admission for patients with severe asthma attacks that persist after initial bronchodilator treatment. This also applies to patients with moderate asthma exacerbations who have had a previous near-fatal asthma attack.

For example, if a patient is experiencing a moderate exacerbation that may be developing into an acute severe exacerbation, hospital referral should be considered. This is evidenced by a PEFR of 50%, which is the lower end of a moderate attack, along with a potentially rising respiratory rate and heart rate. Even if the patient is not bordering on an acute severe exacerbation, a referral should be considered if they have previously had a life-threatening attack and have not responded adequately to nebulizers.

While amoxicillin and prednisolone may be options, it is important to review the patient earlier than 48 hours if a referral to the hospital is not felt to be appropriate. Intramuscular methylprednisolone is considered as an alternative to oral prednisolone if the patient cannot swallow the medication. It is not recommended to increase the inhaled corticosteroid dose during an exacerbation as an alternative to oral corticosteroids.

In summary, understanding NICE guidance on hospital admission for acute asthma exacerbations is crucial for clinicians to provide appropriate care for their patients.

Patients with RA who are taking etanercept are at a higher risk of developing infections, including chest infections and sepsis. If an infection does occur, it is important to discontinue the use of etanercept until the infection has been cleared. Additionally, biologic therapy can increase the risk of TB or reactivation of latent TB, and patients on this type of therapy require regular blood monitoring. This includes a full blood count, urea and electrolytes (with creatinine), and liver function tests initially, followed by monitoring every 6 months once stable, unless there is a clinical need for more frequent monitoring.

Rheumatoid arthritis (RA) management has been transformed by the introduction of disease-modifying therapies in recent years. Patients with joint inflammation should begin a combination of disease-modifying drugs (DMARD) as soon as possible. Other important treatment options include analgesia, physiotherapy, and surgery.

In 2018, NICE updated their guidelines for RA management, recommending DMARD monotherapy with or without a short course of bridging prednisolone as the initial step. Previously, dual DMARD therapy was advocated. To monitor response to treatment, NICE suggests using a combination of CRP and disease activity (using a composite score such as DAS28).

Flares of RA are often managed with corticosteroids, either orally or intramuscularly. Methotrexate is the most commonly used DMARD, but monitoring of FBC & LFTs is essential due to the risk of myelosuppression and liver cirrhosis. Other important side-effects include pneumonitis. Other DMARDs include sulfasalazine, leflunomide, and hydroxychloroquine.

TNF-inhibitors are indicated for patients who have had an inadequate response to at least two DMARDs, including methotrexate. Etanercept is a recombinant human protein that acts as a decoy receptor for TNF-α and is administered subcutaneously. Infliximab is a monoclonal antibody that binds to TNF-α and prevents it from binding with TNF receptors, and is administered intravenously. Adalimumab is also a monoclonal antibody, administered subcutaneously. Risks associated with TNF-inhibitors include reactivation of tuberculosis and demyelination.

Rituximab is an anti-CD20 monoclonal antibody that results in B-cell depletion. Two 1g intravenous infusions are given two weeks apart, but infusion reactions are common. Abatacept is a fusion protein that modulates a key signal required for activation of T lymphocytes, leading to decreased T-cell proliferation and cytokine production. It is given as an infusion but is not currently recommended by NICE.

Cognitive Therapy and Breathing Exercises for Hyperventilation Syndrome

Two studies have shown that cognitive therapy and breathing exercises can effectively treat hyperventilation syndrome. This condition often leads to pleuritic chest pain without any apparent cause. During therapy sessions, specific anxiety triggers can be identified and addressed. However, for those with chronic hyperventilation syndrome, cognitive therapy and breathing exercises can provide relief and improve overall quality of life. With these treatments, patients can learn to control their breathing and reduce symptoms of hyperventilation syndrome.

It is recommended that individuals who are suspected to have asthma undergo both FeNO testing and spirometry with reversibility.

Asthma diagnosis has been updated by NICE guidelines in 2017, which emphasizes the use of objective tests rather than subjective/clinical judgments. The guidance recommends the use of fractional exhaled nitric oxide (FeNO) test, which measures the level of nitric oxide produced by inflammatory cells, particularly eosinophils. Other established objective tests such as spirometry and peak flow variability are still important. All patients aged five and above should have objective tests to confirm the diagnosis. For patients aged 17 and above, spirometry with a bronchodilator reversibility (BDR) test and FeNO test should be performed. For children aged 5-16, spirometry with a BDR test and FeNO test should be requested if there is normal spirometry or obstructive spirometry with a negative BDR test. For patients under five years old, diagnosis should be made based on clinical judgment. The specific points about the tests include a FeNO level of >= 40 ppb for adults and >= 35 ppb for children considered positive, and a FEV1/FVC ratio less than 70% or below the lower limit of normal considered obstructive for spirometry. A positive reversibility test is indicated by an improvement in FEV1 of 12% or more and an increase in volume of 200 ml or more for adults, and an improvement in FEV1 of 12% or more for children.

Therapies for Smoking Cessation

There are various therapies available for smoking cessation, including newer drugs that have been specifically developed for this purpose. One such drug is Varenicline, which is a non-nicotine drug that acts as a partial agonist of the alpha-4 beta-2 nicotinic receptor.

Nicotine is a stimulant that releases dopamine in the brain, leading to addictive effects of smoking. However, nicotine replacement therapy can help replace these effects and reduce addiction to cigarette smoking. Bupropion (Zyban) is another drug that reduces the neuronal uptake of dopamine, serotonin, and norepinephrine.

Clonidine is a second-line agent due to its side effects, but it is an a2-noradrenergic agonist that suppresses sympathetic activity. Nortriptyline, a tricyclic antidepressant with mostly noradrenergic properties, is also an effective agent for smoking cessation.

Overall, there are many options available for those looking to quit smoking, and it is important to work with a healthcare provider to determine the best approach for each individual.

Referral to secondary care for consideration of prophylactic antibiotic treatment is the recommended option for COPD patients who meet certain criteria and continue to have exacerbations. NICE suggests considering prophylactic oral macrolide therapy, such as azithromycin, for individuals who have had more than three exacerbations requiring steroid therapy and at least one exacerbation requiring hospital admission in the previous year.

Referral to secondary care for consideration of nebulisers is not appropriate for this patient as they are not experiencing distressing or disabling breathlessness despite maximal therapy using inhalers.

Referral to secondary care for consideration of phosphodiesterase-4 inhibitors is not applicable for this patient as they do not have severe disease with persistent symptoms and exacerbations despite optimal inhaled and pharmacological therapy.

Starting the patient on long term corticosteroids is not recommended in primary care and requires referral to a respiratory specialist.

Starting the patient on oral mucolytic therapy is not necessary as they do not have a chronic cough productive of sputum.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Investigating and Diagnosing COPD

To diagnose COPD, NICE recommends considering patients over 35 years of age who are smokers or ex-smokers and have symptoms such as chronic cough, exertional breathlessness, or regular sputum production. The following investigations are recommended: post-bronchodilator spirometry to demonstrate airflow obstruction, chest x-ray to exclude lung cancer and identify hyperinflation, bullae, or flat hemidiaphragm, full blood count to exclude secondary polycythaemia, and BMI calculation. The severity of COPD is categorized using the FEV1, with Stage 1 being mild and Stage 4 being very severe. Measuring peak expiratory flow is of limited value in COPD as it may underestimate the degree of airflow obstruction. It is important to note that the grading system has changed following the 2010 NICE guidelines, with Stage 1 now including patients with an FEV1 greater than 80% predicted but a post-bronchodilator FEV1/FVC ratio less than 70%.

What are the indications for long-term oxygen therapy (LTOT) in COPD patients?

In COPD patients, LTOT is typically indicated when their PaO2 is less than 7.3kPa when stable. However, this threshold is increased to less than 8kPa if they have secondary polycythemia, pulmonary hypertension, or peripheral edema. Arterial oxygen concentration should be assessed when stable and with at least two readings taken at least three weeks apart. To achieve the greatest effect, supplementary oxygen should be used for more than 20 hours per day, but a minimum of 15 hours per day is required.

Maintenance oral corticosteroid use is not routinely recommended and should only be considered when it is not possible to fully wean steroids between exacerbations.

As per the 2018 NICE update to the COPD guidelines, LTOT is no longer recommended for current smokers.

Long-Term Oxygen Therapy for COPD Patients

Long-term oxygen therapy (LTOT) is recommended for patients with chronic obstructive pulmonary disease (COPD) who have severe or very severe airflow obstruction, cyanosis, polycythaemia, peripheral oedema, raised jugular venous pressure, or oxygen saturations less than or equal to 92% on room air. LTOT involves breathing supplementary oxygen for at least 15 hours a day using oxygen concentrators.

To assess patients for LTOT, arterial blood gases are measured on two occasions at least three weeks apart in patients with stable COPD on optimal management. Patients with a pO2 of less than 7.3 kPa or those with a pO2 of 7.3-8 kPa and secondary polycythaemia, peripheral oedema, or pulmonary hypertension should be offered LTOT. However, LTOT should not be offered to people who continue to smoke despite being offered smoking cessation advice and treatment, and referral to specialist stop smoking services.

Before offering LTOT, a structured risk assessment should be carried out to evaluate the risks of falls from tripping over the equipment, the risks of burns and fires, and the increased risk of these for people who live in homes where someone smokes (including e-cigarettes).

Overall, LTOT is an important treatment option for COPD patients with severe or very severe airflow obstruction or other related symptoms.

As an ex-smoker, this woman is experiencing a gradual improvement in her consolidation, but she still has a persistent cough. It is recommended that she be referred for further evaluation under the 2 week wait rule to rule out the possibility of lung cancer.

Referral Guidelines for Lung Cancer

Lung cancer is a serious condition that requires prompt diagnosis and treatment. The 2015 NICE cancer referral guidelines provide clear advice on when to refer patients for suspected lung cancer. According to these guidelines, patients should be referred using a suspected cancer pathway referral for an appointment within 2 weeks if they have chest x-ray findings that suggest lung cancer or are aged 40 and over with unexplained haemoptysis.

For patients aged 40 and over who have 2 or more unexplained symptoms such as cough, fatigue, shortness of breath, chest pain, weight loss, or appetite loss, an urgent chest x-ray should be offered within 2 weeks to assess for lung cancer. This recommendation also applies to patients who have ever smoked and have 1 or more of these unexplained symptoms.

In addition, patients aged 40 and over with persistent or recurrent chest infection, finger clubbing, supraclavicular lymphadenopathy or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or thrombocytosis should be considered for an urgent chest x-ray within 2 weeks to assess for lung cancer.

Overall, these guidelines provide clear and specific recommendations for healthcare professionals to identify and refer patients with suspected lung cancer for prompt diagnosis and treatment.

To ensure effective use of an inhaler, it is important to follow proper technique. Asthma UK provides helpful guidance on inhaler usage for different types of inhalers.

For a pressurised metered dose inhaler, it is advised to hold your breath for 10 seconds after inhaling the medication. This allows sufficient time for the medication to reach the airways, rather than being exhaled prematurely.

To use the inhaler, breathe in slowly and steadily while pressing down on the canister in one smooth motion. If a second dose is needed, wait for about 30 seconds before repeating to avoid any interference with the delivery of the medication.

Proper Inhaler Technique for Metered-Dose Inhalers

Metered-dose inhalers are commonly used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, it is important to use them correctly to ensure that the medication is delivered effectively to the lungs. Here is a step-by-step guide to proper inhaler technique:

1. Remove the cap and shake the inhaler.

2. Breathe out gently.

3. Place the mouthpiece in your mouth and begin to breathe in slowly and deeply.

4. As you start to inhale, press down on the canister to release the medication. Continue to inhale steadily and deeply.

5. Hold your breath for 10 seconds, or as long as is comfortable.

6. If a second dose is needed, wait approximately 30 seconds before repeating steps 1-5.

It is important to note that inhalers should only be used for the number of doses specified on the label. Once the inhaler is empty, a new one should be started. By following these steps, patients can ensure that they are using their inhaler correctly and receiving the full benefits of their medication.

Diagnostic Tests for COPD

In addition to spirometry, it is recommended that patients with COPD undergo several diagnostic tests at the time of diagnosis. These tests include a chest x-ray to rule out other potential lung pathologies, a full blood count to assess for anemia or polycythemia, and a calculation of body mass index.

Depending on the patient’s history and examination findings, other diagnostic tests may be necessary. For example, if asthma is suspected, serial peak flow measurements may be indicated. If signs or symptoms of cor pulmonale are present, an ECG or echocardiogram may be necessary. By conducting these diagnostic tests, healthcare professionals can accurately diagnose and manage COPD in their patients.

Causes of Clubbing and Mesothelioma as a Differential Diagnosis

Clubbing can be caused by respiratory, gastroenterological, and cardiac conditions. Respiratory causes include cystic fibrosis, bronchiectasis, lung carcinoma, fibrosis, and mesothelioma. Gastroenterological causes include lymphoma, inflammatory bowel disease, and cirrhosis. Cardiac causes include cyanotic heart disease, atrial myxoma, and bacterial endocarditis.

In this case, the patient presents with clubbing and respiratory symptoms, making it difficult to determine the exact cause. However, the patient’s occupational history as a dock worker puts them at risk for mesothelioma, a type of cancer caused by exposure to asbestos. Mesothelioma is more likely than other options due to the patient’s age, clinical and chest x-ray findings of pleural thickening and effusion. It is important to consider mesothelioma as a differential diagnosis in patients with clubbing and a history of asbestos exposure.

A provoked pulmonary embolism, which occurred after surgery and immobilisation in a middle-aged man, typically requires treatment for at least 3 months. However, the duration of treatment may need to be extended or specialist referral may be necessary depending on the patient’s leg and respiratory symptoms. Indefinite anticoagulation is not recommended unless the problem is recurrent or the patient has thrombophilia. Referral to a haematologist is also not necessary unless the treatment is unsuccessful or the patient experiences further thrombosis issues. Anticoagulation for 6 months may be considered for unprovoked pulmonary embolism, but in this case, the patient’s condition was provoked by surgery and immobilisation.

Management of Pulmonary Embolism

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management. The guidelines recommend using apixaban or rivaroxaban as the first-line treatment for PE, followed by LMWH, dabigatran, edoxaban, or a vitamin K antagonist (VKA) if necessary. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation depends on whether the VTE was provoked or unprovoked, with treatment typically lasting for at least three months. Patients with unprovoked VTE may continue treatment for up to six months, depending on their risk of recurrence and bleeding.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Other invasive approaches may also be considered where appropriate facilities exist. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak, and further studies are needed.

Legionnaires Disease: Causes, Symptoms, and Treatment

Legionnaires disease is a type of pneumonia caused by the Gram-negative bacillus, Legionella pneumophilia. The disease is usually associated with contaminated water cooling systems, air conditioning units, or showers. However, sporadic cases can also occur. People who travel and stay in hotels or resorts with poorly maintained air conditioning or showers are at risk of exposure to the bacteria.

The symptoms of Legionnaires disease can vary and may include gastrointestinal upset, flu-like symptoms, diarrhea, jaundice, headache, and confusion. Patients may also experience a decrease in their white blood cell count, resulting in lymphopenia. Additionally, the disease can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to hyponatremia. Abnormal liver and renal biochemistry occur in about half of patients.

Amoxicillin is not an effective treatment for Legionnaires disease. Instead, macrolides such as erythromycin or clarithromycin are typically used. Some doctors prefer to use quinolones as the first choice of treatment.

If a patient with COPD is still experiencing breathlessness despite using SABA/SAMA and doesn’t exhibit any features that suggest responsiveness to steroids or asthma, the recommended course of action according to the 2018 NICE guidelines is to introduce a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

According to NICE guidelines, oral antibiotics should only be prescribed in cases of acute exacerbation of COPD if there is purulent sputum or clinical signs of pneumonia. As this patient doesn’t exhibit these symptoms, prescribing oral antibiotics is not recommended.

Instead, increasing the frequency of inhaled bronchodilators is a suitable step in managing this patient’s acute exacerbation of COPD. The patient’s mild wheeze should improve with this treatment.

NICE recommends a review in 6 weeks if there is no rapid or significant worsening of symptoms. However, if symptoms worsen rapidly or significantly, the patient should be reviewed sooner by the appropriate healthcare provider.

Prescribing oral steroids is appropriate for managing this patient’s acute exacerbation of COPD as it can reduce inflammation and improve symptoms.

It is also appropriate to discuss smoking cessation with the patient, as they are still smoking. However, it should be documented if the patient is not interested in considering smoking cessation. Any opportunity for smoking cessation advice should be utilized.

Acute exacerbations of COPD are a common reason for hospitalization in developed countries. The most common causes of these exacerbations are bacterial infections, such as Haemophilus influenza, Streptococcus pneumoniae, and Moraxella catarrhalis, as well as respiratory viruses, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators, such as beta adrenergic agonists and muscarinic antagonists, should also be used. Steroid therapy and IV theophylline may be considered, and non-invasive ventilation may be used for patients with type 2 respiratory failure. BiPAP is typically used with initial settings of EPAP at 4-5 cm H2O and IPAP at 10-15 cm H2O.

Antibiotic Prophylaxis for Pertussis

When managing a suspected or confirmed case of pertussis, it is important to offer prophylactic antibiotics to reduce transmission if the case presents within 21 days of onset and a vulnerable contact is present in the household. All household contacts, regardless of age or immunisation status, should be offered antibiotics. Antibiotics may not alter the clinical course of the illness, but they can eliminate the organism from the respiratory tract, reducing person-to-person transmission. Vulnerable contacts include newborn infants, unimmunised or partially immunised infants or children up to 10 years, pregnant women, healthcare workers, immunocompromised individuals, and those with chronic illnesses. The maternal pertussis vaccine programme has been highly effective in preventing disease for infants less than 2 months of age. Therefore, the definition of vulnerable infants has been amended to include unimmunised infants born ≤32 weeks, unimmunised infants born >32 weeks whose mothers did not receive maternal pertussis vaccine after 16 weeks and at least 2 weeks before delivery, and infants aged 2 months or over who are unimmunised or partially immunised. It is important for GPs to understand and implement national guidelines for respiratory problems, including the management of pertussis.

Process of Elimination in Tricky Questions

When faced with a tricky question, it is important to stay calm and think through the options. One useful technique is the process of elimination. For example, in a question about the best antibiotic for a patient with a penicillin allergy who is taking aminophylline, you can immediately eliminate options that contain penicillin. Macrolides and ciprofloxacin can interact with aminophylline, increasing its plasma concentration, so you can eliminate those options as well. By process of elimination, you can arrive at the best answer, which in this case is doxycycline. Practicing this approach can help you tackle tricky questions and improve your performance in exams. Remember to take your time, read the question carefully, and eliminate options that do not fit the criteria.

According to the updated NICE guidelines in 2018, all individuals who are suspected to have chronic heart failure should undergo an NT-proBNP test as the initial diagnostic test, irrespective of their history of myocardial infarction.

Diagnosis of Chronic Heart Failure

Chronic heart failure is a serious condition that requires prompt diagnosis and management. In 2018, the National Institute for Health and Care Excellence (NICE) updated its guidelines on the diagnosis and management of chronic heart failure. According to the new guidelines, all patients should undergo an N-terminal pro-B-type natriuretic peptide (NT‑proBNP) blood test as the first-line investigation, regardless of whether they have previously had a myocardial infarction or not.

Interpreting the NT-proBNP test is crucial in determining the severity of the condition. If the levels are high, specialist assessment, including transthoracic echocardiography, should be arranged within two weeks. If the levels are raised, specialist assessment, including echocardiogram, should be arranged within six weeks.

BNP is a hormone produced mainly by the left ventricular myocardium in response to strain. Very high levels of BNP are associated with a poor prognosis. The table above shows the different levels of BNP and NTproBNP and their corresponding interpretations.

It is important to note that certain factors can alter the BNP level. For instance, left ventricular hypertrophy, ischaemia, tachycardia, and right ventricular overload can increase BNP levels, while diuretics, ACE inhibitors, beta-blockers, angiotensin 2 receptor blockers, and aldosterone antagonists can decrease BNP levels. Therefore, it is crucial to consider these factors when interpreting the NT-proBNP test.

Managing Chronic Asthma in Adults

When managing chronic asthma in adults, it is important to consider the patient’s current treatment plan and symptoms. In this scenario, the patient is already taking a combination inhaler and is experiencing suboptimal control of her asthma. It is important to note that this is not an acute attack and the children’s guidelines do not apply. Antibiotics are not recommended as the symptoms are not consistent with an infective exacerbation. Increasing the usage of salbutamol is also not recommended as the patient needs better overall control of her symptoms. Instead, the dose of the inhaled corticosteroid should be increased, which is in line with the next step in the treatment of asthma in adults according to the British Thoracic Society guidelines. It is important for healthcare professionals to be familiar with both SIGN and NICE guidance and be able to compare and contrast their advice.

Methotrexate can lead to pulmonary fibrosis, while there is no evidence to suggest that terbinafine, paracetamol, montelukast, and tramadol have this side effect. The onset of pulmonary fibrosis due to low-dose methotrexate use can occur within weeks to months.

Methotrexate is an antimetabolite that hinders the activity of dihydrofolate reductase, an enzyme that is crucial for the synthesis of purines and pyrimidines. It is a significant drug that can effectively control diseases, but its side-effects can be life-threatening. Therefore, careful prescribing and close monitoring are essential. Methotrexate is commonly used to treat inflammatory arthritis, especially rheumatoid arthritis, psoriasis, and acute lymphoblastic leukaemia. However, it can cause adverse effects such as mucositis, myelosuppression, pneumonitis, pulmonary fibrosis, and liver fibrosis.

Women should avoid pregnancy for at least six months after stopping methotrexate treatment, and men using methotrexate should use effective contraception for at least six months after treatment. Prescribing methotrexate requires familiarity with guidelines relating to its use. It is taken weekly, and FBC, U&E, and LFTs need to be regularly monitored. Folic acid 5mg once weekly should be co-prescribed, taken more than 24 hours after methotrexate dose. The starting dose of methotrexate is 7.5 mg weekly, and only one strength of methotrexate tablet should be prescribed.

It is important to avoid prescribing trimethoprim or co-trimoxazole concurrently as it increases the risk of marrow aplasia. High-dose aspirin also increases the risk of methotrexate toxicity due to reduced excretion. In case of methotrexate toxicity, the treatment of choice is folinic acid. Overall, methotrexate is a potent drug that requires careful prescribing and monitoring to ensure its effectiveness and safety.

Adding an inhaled long-acting beta-2 agonist (LABA) would not be the appropriate course of action at this time. It should only be considered as an add-on therapy if the patient’s asthma remains uncontrolled despite regular use of inhaled corticosteroids.

Similarly, adding a leukotriene receptor antagonist (LTRA) would not be recommended at this stage. It should only be considered if the patient’s asthma remains uncontrolled despite using a combination of LABA and ICS, or if low-dose ICS is insufficient.

Doubling the dose of beclomethasone dipropionate would also not be the correct approach. This would result in a medium dose of ICS, which is only recommended if the patient remains symptomatic despite a combination of low-dose ICS and LABA. Alternatively, an LTRA may be added.

Stopping beclomethasone dipropionate and relying solely on salbutamol as needed would not be advisable. Any reduction in ICS should be done gradually to minimize the risk of worsening symptoms.

Stepping Down Asthma Treatment: BTS Guidelines

The British Thoracic Society (BTS) recommends that asthma treatment should be reviewed every three months to consider stepping down treatment. However, the guidelines do not suggest a strict move from one step to another but rather advise taking into account the duration of treatment, side-effects, and patient preference. When reducing the dose of inhaled steroids, the BTS suggests doing so by 25-50% at a time.

Patients with stable asthma may only require a formal review once a year. However, if a patient has recently had an escalation of asthma treatment, they are likely to be reviewed more frequently. It is important to follow the BTS guidelines to ensure that patients receive the appropriate level of treatment for their asthma and to avoid unnecessary side-effects.

NICE suggests including an antibiotic only when the sputum shows signs of being purulent.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Most Likely Cause of Bronchospasm in a Patient with Asthma

Examiners often use terms like most likely to test a candidate’s ability to reason. In primary care, where there may be multiple causes, prioritizing treatment options is crucial. In a patient with a history of asthma experiencing bronchospasm, propranolol is the most likely cause, and its use should be avoided. While bronchospasm is reported in aspirin-sensitive patients and paradoxical bronchospasm in some patients treated with salmeterol, beta-blockers like propranolol can precipitate bronchospasm and should be avoided in patients with asthma.

According to the British National Formulary, beta-blockers should be avoided in patients with a history of asthma. However, in some cases, a cardioselective beta-blocker may be necessary for a co-existing condition like heart failure or following a myocardial infarction. In such situations, a specialist should initiate treatment with a low dose of a cardioselective beta-blocker like atenolol, bisoprolol fumarate, metoprolol tartrate, nebivolol, or acebutolol. These drugs have a lesser effect on airways resistance but are not free of this side-effect.

ACE inhibitors like ramipril are inhibitors of the metabolism of bradykinin and can cause cough. Bronchospasm is also reported as an adverse event associated with ACE inhibition, although it is very rare.

One of the few interventions that has been proven to increase survival in COPD after quitting smoking is long-term oxygen therapy (LTOT). Patients with a pO2 level below 7.3 kPa should be offered LTOT, as well as those with a pO2 level between 7.3 – 8 kPa who have secondary polycythemia, nocturnal hypoxemia, peripheral edema, or pulmonary hypertension.

The National Institute for Health and Care Excellence (NICE) updated its guidelines on the management of chronic obstructive pulmonary disease (COPD) in 2018. The guidelines recommend general management strategies such as smoking cessation advice, annual influenza vaccination, and one-off pneumococcal vaccination. Pulmonary rehabilitation is also recommended for patients who view themselves as functionally disabled by COPD.

Bronchodilator therapy is the first-line treatment for patients who remain breathless or have exacerbations despite using short-acting bronchodilators. The next step is determined by whether the patient has asthmatic features or features suggesting steroid responsiveness. NICE suggests several criteria to determine this, including a previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time, and substantial diurnal variation in peak expiratory flow.

If the patient doesn’t have asthmatic features or features suggesting steroid responsiveness, a long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) should be added. If the patient is already taking a short-acting muscarinic antagonist (SAMA), it should be discontinued and switched to a short-acting beta2-agonist (SABA). If the patient has asthmatic features or features suggesting steroid responsiveness, a LABA and inhaled corticosteroid (ICS) should be added. If the patient remains breathless or has exacerbations, triple therapy (LAMA + LABA + ICS) should be offered.

NICE only recommends theophylline after trials of short and long-acting bronchodilators or to people who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients who have optimised standard treatments and continue to have exacerbations. Mucolytics should be considered in patients with a chronic productive cough and continued if symptoms improve.

Cor pulmonale features include peripheral oedema, raised jugular venous pressure, systolic parasternal heave, and loud P2. Loop diuretics should be used for oedema, and long-term oxygen therapy should be considered. Smoking cessation, long-term oxygen therapy in eligible patients, and lung volume reduction surgery in selected patients may improve survival in patients with stable COPD. NICE doesn’t recommend the use of ACE-inhibitors, calcium channel blockers, or alpha blockers

Management of Acute Asthma Symptoms

Several important points should be considered when managing a patient with acute asthma symptoms. Firstly, it is important to note if the patient is already taking preventative treatment for asthma. If they are, an increase in the use of their salbutamol inhaler may indicate that their symptoms are worse than usual. Secondly, recent viral infections can trigger asthma symptoms. Additionally, the absence of discoloured thick phlegm and fever makes it less likely that the patient has a bacterial infection and therefore doesn’t require antibiotic therapy.

When managing acute asthma symptoms, it is important to note that changing inhalers may not be appropriate at this stage. Oxygen therapy is not necessary if the patient’s oxygen saturations are above 94% in air. A nebuliser may not be indicated if the patient’s breathing rate is not compromised and they are clinically stable. It may be beneficial to initially try a salbutamol inhaler before ipratropium bromide. These considerations can help guide the management of acute asthma symptoms.

To alleviate his symptoms, the patient is taking his medication three times daily. Despite his condition, he remains alert and capable of speaking in complete sentences while at rest. His vital signs are as follows: temperature of 37.1ºC, pulse rate of 116/min, blood pressure of 118/70 mmHg, and respiratory rate of 2.

Management of Acute Asthma

Acute asthma is classified into moderate, severe, life-threatening, and near-fatal categories by the British Thoracic Society (BTS). Patients with life-threatening features should be treated as having a life-threatening attack. Further assessment may include arterial blood gases for patients with oxygen sats < 92%, and a chest x-ray is not routinely recommended unless there is life-threatening asthma, suspected pneumothorax, or failure to respond to treatment. Admission is necessary for all patients with life-threatening asthma, and patients with features of severe acute asthma should also be admitted if they fail to respond to initial treatment. Oxygen therapy is important for hypoxaemic patients, and bronchodilation with short-acting beta₂-agonists (SABA) is recommended. All patients should be given 40-50 mg of prednisolone orally (PO) daily, and nebulised ipratropium bromide may be used in severe or life-threatening cases. The evidence base for IV magnesium sulphate is mixed, and IV aminophylline may be considered following consultation with senior medical staff. Patients who fail to respond require senior critical care support and should be treated in an appropriate ITU/HDU setting. Criteria for discharge include being stable on their discharge medication, inhaler technique checked and recorded, and PEF >75% of best or predicted.

Understanding Tachycardia and Bradycardia in Acute Asthma

Tachycardia is a common symptom in acute asthma, but severe attacks may also lead to episodes of bradycardia. A peak flow measurement of only 30% of predicted indicates severe airway obstruction and requires immediate admission and aggressive treatment. While oximetry is useful for assessing oxygenation, it cannot provide information on CO2 retention or acid-base status. Therefore, high-flow oxygen should always be administered in the management of acute asthma.

Understanding the symptoms and measurements associated with acute asthma is crucial for effective management. Tachycardia and bradycardia are two possible heart rate changes that may occur during an asthma attack. Additionally, a peak flow measurement of 30% or less of predicted indicates severe airway obstruction and requires prompt medical attention. While oximetry is useful for assessing oxygenation, it cannot provide a complete picture of the patient’s respiratory status. Therefore, high-flow oxygen should always be given to patients with acute asthma.

Management of Suspected Pulmonary Embolism

When a patient presents with sudden onset breathlessness, haemoptysis, pleuritic pain, hypotension, tachycardia, increased respiratory rate, and low oxygen saturations, pulmonary embolism (PE) should be suspected. It is important to note any risk factors that may increase the likelihood of an embolism. The absence of signs of deep vein thrombosis doesn’t exclude the possibility of a PE.

Immediate admission to the hospital should be arranged for patients with suspected PE who have signs of haemodynamic instability or are pregnant or have given birth within the past 6 weeks. Management should not be delayed for results of a chest X-ray or ECG. Therefore, the correct option is to arrange immediate transfer to the hospital by blue light. Prescribing a non-steroidal anti-inflammatory drug fails to appreciate the possibility of pulmonary embolism and should not be selected.

In summary, prompt recognition and management of suspected PE is crucial to prevent morbidity and mortality.

Urgent Referral for Chest X-Ray in Patients with Chronic Respiratory Problems

Unexplained changes in existing symptoms in patients with underlying chronic respiratory problems should prompt an urgent referral for chest x-ray. According to NICE guidelines on the recognition and referral of suspected cancer, an urgent chest x-ray should be offered to assess for lung cancer in people aged 40 and over with specific unexplained symptoms or risk factors.

In patients with known COPD, the recent onset of finger clubbing should not be automatically assumed to be due to the pre-existing lung disease. Finger clubbing can occur in various types of lung cancer and mesothelioma, and it is less common in COPD alone. Therefore, an urgent referral for chest x-ray is necessary to assess for possible underlying malignancy. Early detection and treatment can significantly improve the prognosis and quality of life for patients with lung cancer.

Sjogren’s Syndrome: A Multi-System Diagnosis

This patient’s chest symptoms, along with systemic symptoms and dry eyes and mouth, suggest a possible multi-system diagnosis. Sjogren’s syndrome is a condition that should be considered, especially if the patient is a woman in her 5th or 6th decade. Men and younger people can also be affected.

Sjogren’s syndrome is characterized by various symptoms, including pulmonary fibrosis, sicca symptoms (dry eyes and mouth), Raynaud’s phenomenon, and arthralgia. Anti-Ro and anti-La antibodies are useful diagnostic tools in identifying this condition.

It is important to recognize the potential for a multi-system diagnosis in patients presenting with a combination of symptoms. In this case, Sjogren’s syndrome should be considered and appropriate testing should be performed to confirm the diagnosis.

During pregnancy, it is safe to use short-acting/long-acting beta 2-agonists, inhaled and oral corticosteroids as recommended by the British Thoracic Society (BTS) guidelines, even if the patient has asthma that is not well-controlled with a SABA.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 British Thoracic Society (BTS) guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist, not a LABA. NICE doesn’t follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. It should be noted that NICE doesn’t recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance.

The steps for managing asthma in adults are as follows: for newly-diagnosed asthma, a short-acting beta agonist (SABA) is recommended. If the patient is not controlled on the previous step or has symptoms >= 3/week or night-time waking, a SABA + low-dose inhaled corticosteroid (ICS) is recommended. For step 3, a SABA + low-dose ICS + leukotriene receptor antagonist (LTRA) is recommended. Step 4 involves a SABA + low-dose ICS + long-acting beta agonist (LABA), and LTRA should be continued depending on the patient’s response. Step 5 involves a SABA +/- LTRA, and switching ICS/LABA for a maintenance and reliever therapy (MART) that includes a low-dose ICS. Step 6 involves a SABA +/- LTRA + medium-dose ICS MART, or changing back to a fixed-dose of a moderate-dose ICS and a separate LABA. Step 7 involves a SABA +/- LTRA + one of the following options: increasing ICS to high-dose (only as part of a fixed-dose regime, not as a MART), a trial of an additional drug (for example, a long-acting muscarinic receptor antagonist or theophylline), or seeking advice from a healthcare professional with expertise in asthma.

It is important to note that the definitions of what constitutes a low, moderate, or high-dose ICS have changed. For adults, <= 400 micrograms budesonide or equivalent is considered a low dose, 400 micrograms - 800 micrograms budesonide or equivalent is a moderate dose, and > 800 micrograms budes

Step-Up Treatment for COPD Patients

When a patient with COPD is only taking salbutamol inhalers and their FEV1 is less than 50%, it may be necessary to step up their treatment. One option is to add a LABA+ICS, which can help improve lung function and reduce symptoms. However, it’s important to note that a LAMA should not be used in combination with an ICS. While adding a regular ICS may be considered in asthma treatment, it is not typically part of the step-up approach for COPD. Additionally, a SAMA can be an alternative to salbutamol inhalers, but it is not intended as a step-up treatment. By carefully considering the best options for each patient, healthcare providers can help manage COPD symptoms and improve quality of life.